Clinical trials: Paranoia
Paranoia, Schizophrenia
Oxytocin Treatment of Schizophrenia
Purpose: Test whether intranasal administration of the neuropeptide, oxytocin, improves social cognition, social functioning and decreases paranoia and other psychotic symptoms in schizophrenia.
- Conditions
- Paranoia, Schizophrenia, Schizoaffective Disorder
- Trial name
- OTS (NCT01028677)
- Testing
- intranasal spray with oxytocin, nasal spray without oxytocin
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of North Carolina, Chapel Hill
Schizophrenia
Study of Efficacy of PEAR-004 in Schizophrenia
The purpose of the study was to determine in patients currently being administered antipsychotic pharmacotherapy whether PEAR-004 could further reduce symptoms of schizophrenia as measured by the Positive and Negative Syndrome…
- Trial name
- NCT03751280
- Testing
- PEAR-004
- Where
- 6 sites in United States
- Volunteers
- 112 people
- Sponsor
- Novartis Pharmaceuticals
Paranoia, Schizophrenia-spectrum Diagnosis
The Street Smart Group: A Feasibility Trial of a Group Intervention Targeting Anxiety Processes in Paranoia
This study aims to evaluate a novel group psychological intervention targeting anxiety triggered by urban environments for people with paranoia.
- Trial name
- NCT02408198
- Testing
- Anxiety intervention
- Where
- United Kingdom
- Volunteers
- 18 people
- Sponsor
- King's College London